Evaluating Noninferiority With Clinically Interpretable Statistics for the PROSELICA Study to Assess Treatment Efficacy of a Reduced Dose of Cabazitaxel for Treating Metastatic Prostate Cancer
- PMID: 29373099
- DOI: 10.1200/JCO.2017.75.9829
Evaluating Noninferiority With Clinically Interpretable Statistics for the PROSELICA Study to Assess Treatment Efficacy of a Reduced Dose of Cabazitaxel for Treating Metastatic Prostate Cancer
Comment in
-
Reply to M. Horiguchi et al.J Clin Oncol. 2018 Mar 10;36(8):826-827. doi: 10.1200/JCO.2017.76.3748. Epub 2018 Jan 26. J Clin Oncol. 2018. PMID: 29373098 No abstract available.
Comment on
-
Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA.J Clin Oncol. 2017 Oct 1;35(28):3198-3206. doi: 10.1200/JCO.2016.72.1076. Epub 2017 Aug 15. J Clin Oncol. 2017. PMID: 28809610 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
